Results 91 to 100 of about 17,322 (222)
Journal of the International AIDS Society, Volume 29, Issue S1, June 2026.ABSTRACT Introduction Peripartum adolescent girls and young women (AGYW) with HIV have lower viral suppression compared to older women. But the recently introduced dolutegravir‐based regimens and psychosocial peer motivation may improve viral control.
Tariro D. Chawana‐Mutingwende +25 more
wiley +1 more source
Caffeoylquinic acids as inhibitors for HIV-I protease and HIV-I integrase: a molecular docking study [PDF]
, 2016 Caffeoylquinic acids are ubiquitous phenolic compounds with several health benefits to humans and they have been shown to be promisinganti-HIV compounds.
Castilho, Paula C. +2 more
core
Journal of the International AIDS Society, Volume 29, Issue 6, June 2026.ABSTRACT Introduction Despite increasing access to HIV treatment and care, HIV‐associated deaths remain high. We aimed to summarize global and regional trends in risk and causes of death among people living with HIV (PLHIV) admitted to hospital. Methods We conducted a systematic search across eight databases on 23 April 2023, identifying studies that ...
Rachael M. Burke +11 more
wiley +1 more source
Molecules, 2011 Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). In recent years our research group has been engaged in the stucture-function study of this enzyme and in the development
Alba Chimirri +6 more
doaj +1 more source
Acta Crystallographica Section D, Volume 82, Issue 6, Page 587-602, June 2026.This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik +44 more
wiley +1 more source
HIV Medicine, Volume 27, Issue 6, Page 886-895, June 2026.Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno +9 more
wiley +1 more source
VirusesWith the widespread use of integrase inhibitors and the expanding use of long-acting cabotegravir in both pre-exposure prophylaxis and antiretroviral treatment, molecular surveillance on the transmission of integrase resistance has regained clinical ...
Kaja Mielczak +14 more
doaj +1 more source
PLoS ONE, 2013 Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda +6 more
doaj +1 more source
The impact of accumulating immune adaptation in circulating strains of HIV‐1
HIV Medicine, Volume 27, Issue 6, Page 918-934, June 2026.Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi +7 more
wiley +1 more source
HIV-1 Integrase Pharmacophore: Discovery of Inhibitors through Three-Dimensional Database Searching†
, 2016 Starting from a known inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase (IN), caffeic acid phenethyl ester (CAPE), a putative three-point pharmacophore for binding of inhibitors to IN was derived.
Marc C. Nicklaus (1336209) +7 more
core +1 more source